
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs Inc. is positioned favorably in the biotechnology sector due to its focus on innovative treatments for inflammatory bowel disease (IBD) and other immune-mediated conditions, with its lead program, SL-325, being a potential first-in-class therapeutic. The increasing adoption of biologics among patients with Crohn's Disease (CD) and Ulcerative Colitis (UC) in the U.S., rising from 22% to 44% and 5% to 16% respectively from 2007 to 2015, indicates a robust market demand for effective therapies, which supports Shattuck Labs's prospects. Additionally, the company's strategic development of SL-425 and multiple preclinical DR3-based bispecific antibodies reinforces its commitment to addressing unmet medical needs in IBD, potentially translating to significant market share growth as it builds on its strong efficacy and safety profile.
Bears say
Shattuck Labs Inc faces significant risks regarding the efficacy and safety of its lead programs, specifically the SL-325 and SL-425 candidates, as their success is uncertain and could be hindered by high immunogenicity or safety signals. Furthermore, the market growth and adoption rates for advanced therapies in inflammatory bowel disease (IBD) may be underestimated, which could negatively impact the commercial viability of their treatments. Lastly, a potential decline in surgery rates due to the increasing use of biologics may limit the patient population that could benefit from Shattuck's products, posing an additional challenge to their market prospects.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares